AI-generated · cited to primary sources · not investment advice
Johnson & Johnson Common Stock (JNJ) Mar 2026 Filing Analysis
Does management do what it says?
The impact of biosimilar competition for STELARA is now clearly visible in the financials, causing a 6.1% drag on worldwide operational sales growth in the first nine months of 2025. (1 met across 1 tracked commitment)
“The Company expects continued launches of biosimilar versions of STELARA globally which will continue to negatively impact the Company’s sales of STELARA.”
The company maintains sufficient liquidity to cover remaining litigation obligations, though the talc reserve has been adjusted following the dismissal of bankruptcy proceedings. (1 in progress across 1 tracked commitment)
“The Company anticipates that operating cash flows... will continue to provide sufficient resources to fund operating needs, including the Company’s remaining balance of approximately $3.4 billion related to talc matters... and the remaining approximately $1.1 billion related to opioid settlements.”
The company plans to complete the separation of its Orthopaedics business within a specific timeframe. — target: completion of separation (+1 more commitment)
“In October 2025, the Company announced its intention to separate its Orthopaedics business. The Company continues to explore multiple paths to effect the planned separation with a targeted completion within 18 to 24 months after the initial announcement.”
Management expects the launch of biosimilar versions of SIMPONI to reduce future sales in Europe and the U.S. — target: reduction in future sales
“Biosimilars are pursuing regulatory approval for SIMPONI, which would likely result in a reduction in future sales, potentially in the first half of 2026 in Europe and second half of 2026 in the U.S.”
Management expects generic competition for OPSUMIT in the U.S. to result in a reduction in future sales. — target: reduction in future sales (+1 more commitment)
“The Company expects generic competition for OPSUMIT in the U.S. in the second half of 2026, which would likely result in a reduction in future sales.”
See the full cited Management analysis of Johnson & Johnson Common Stock
How durable is the business?
Profitability in the pharmaceutical segment improved significantly, with margins expanding from 35.0% to 38.6%. This was driven by lower R&D spending as a percentage of sales and the absence of large one-time acquisition charges seen in the prior year. (2 expanding across 1 engine)
“Innovative Medicine segment sales in the fiscal first quarter of 2026 were $15.4 billion, an increase of 11.2%... segment income before tax as a percent of sales... was 34.5%”
The segment remains the primary revenue engine, growing to a 64.0% share of total sales. Growth was driven by Oncology (up 21.1%) and Neuroscience (up 3.2%), though partially offset by a significant decline in Stelara sales due to biosimilar competition. (5 expanding across 1 engine)
“MedTech segment sales in the fiscal first quarter of 2026 were $8.6 billion, an increase of 7.7%... segment income before tax as a percent of sales... was 14.3%”
The balance sheet remains a core advantage but saw a decrease in cash and an increase in debt to fund major acquisitions. Net debt rose to $27.8 billion from $12.1 billion following the $14.5 billion Intra-Cellular acquisition. (2 shifted)
“As of March 29, 2026, the Company had cash, cash equivalents and marketable securities of approximately $22.1 billion... The Company anticipates that operating cash flows... will continue to provide sufficient resources to fund operating needs.”
The moat is facing a significant challenge as Stelara, a key immunology drug, experienced a 38.6% worldwide sales decline due to the entry of biosimilar competitors (lower-cost versions of biologic drugs). (3 contracting, 1 shifted)
“The Company’s Innovative Medicine subsidiaries have brought lawsuits against generic companies... seeking an order enjoining the defendant from marketing a generic version of a product before the expiration of the relevant patents.”
Johnson & Johnson is a global healthcare giant that develops and sells prescription drugs and medical devices, focusing on Innovative Medicine and MedTech. (+1 more finding)
“The Company is organized into two business segments: Innovative Medicine and MedTech.”
See the full cited Business Model analysis of Johnson & Johnson Common Stock
Where does growth come from?
The Cardiovascular franchise is showing significant acceleration, with operational growth jumping to 17.7% this quarter, largely driven by the acquisition of Shockwave Medical and strong adoption of Abiomed's Impella products. (5 accelerating across 5 signals, 1 leading indicator)
“Innovative Medicine segment sales in the fiscal first quarter of 2026 were $15.4 billion, an increase of 11.2% as compared to the same period a year ago”
The Cardiovascular franchise is accelerating significantly, driven by the acquisition of Shockwave and strong performance in Electrophysiology, which grew 16.5% operationally in the first nine months. (1 accelerating, 2 new trend, 2 steady across 5 signals, 2 leading indicators)
“In October 2025, the Company announced its intention to separate its Orthopaedics business... with a targeted completion within 18 to 24 months after the initial announcement.”
J&J is accelerating its capacity building, with capital expenditures for property, plant, and equipment rising to over $1 billion this quarter, up from $795 million last year. (1 accelerating, 1 decelerating, 3 steady across 5 signals, 2 leading indicators)
“Additions to Property, Plant & Equipment... Worldwide total $1,049 [million]”
The reported margin shows a massive one-time acceleration (from 17.4% to 62.3%) due to the reversal of a $7.0 billion talc litigation reserve. Excluding this, underlying margins are pressured by unfavorable currency and the Shockwave acquisition costs. (2 accelerating, 3 reversing across 5 signals)
“Earnings before provision for taxes on income... 24.9% [of sales] versus 62.3% for the same period a year ago.”
A major growth hurdle is the loss of patent protection for STELARA, which caused a significant 60% drop in sales for that specific drug this quarter. — STELARA Sales Decline: 59.7% decline YoY
“STELARA... Worldwide 656 [million]... (59.7) [percent change]”
See the full cited Future Growth analysis of Johnson & Johnson Common Stock
What could break the thesis?
The risk is easing financially as the company reversed approximately $7.0 billion of its talc reserve following a bankruptcy court dismissal, though it remains in the tort system to litigate remaining claims. (2 easing, 2 stable, 1 intensifying, 2 high-severity)
“As of March 29, 2026, there are approximately 75,000 plaintiffs in the United States with direct claims against the Company... the total present value of the reserve for talc related matters is approximately $3.4 billion”
The risk is intensifying as biosimilar competition is now materially impacting sales, causing a 39.5% decline in STELARA revenue for the first nine months of 2025. (2 intensifying, 1 stable, 1 high-severity)
“In the fiscal first quarter of 2026, the negative impact of the STELARA sales decline, due to biosimilar competition, on worldwide operational sales was approximately 5.4%.”
The risk is stable but remains a drag on earnings, with a new Surgery restructuring program estimated to cost up to $1.0 billion over the next two years. (1 stable, 4 intensifying)
“The MedTech segment income before tax as a percent of sales in the fiscal first quarter of 2026 was 14.3% versus 17.7% for the same period a year ago... primarily driven by... Tariffs included in Cost of products sold”
The risk is intensifying as total debt reached $50.8 billion, up from $41.5 billion a year ago, driven by the $14.5 billion Intra-Cellular acquisition and $12.6 billion Shockwave acquisition. (3 intensifying, 1 stable)
“The Company had... a net debt position of $32.9 billion as compared to the prior year fiscal first quarter net debt position of $13.5 billion.”
The risk is stable but remains a focus as the company reiterated its intention to separate the business with a targeted completion in 18 to 24 months. (3 stable)
“MedTech includes: Orthopaedics Separation related charge of $0.1 billion in the fiscal first quarter of 2026.”
See the full cited Risk analysis of Johnson & Johnson Common Stock
AI-generated informational research only. ThesisLoop is not investment advice, a stock recommendation, or a guarantee of returns.